Immunomodulatory role of mesenchymal stem cell therapy in liver fibrosis
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Liver fibrosis is a fibrogenic and inflammatory process that results from hepatocyte injury and is characterized by hepatic architectural distortion and resultant loss of liver function. There is no effective treatment for advanced fibrosis other than liver transplantation, but it is limited by expensive costs, immune rejection, and postoperative complications. With the development of regenerative medicine in recent years, mesenchymal stem cell (MSCs) transplantation has become the most promising treatment for liver fibrosis. The underlying mechanisms of MSC anti-fibrotic effects include hepatocyte differentiation, paracrine, and immunomodulation, with immunomodulation playing a central role. This review discusses the immune cells involved in liver fibrosis, the immunomodulatory properties of MSCs, and the immunomodulation mechanisms of MSC-based strategies to attenuate liver fibrosis. Meanwhile, we discuss the current challenges and future directions as well.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms of hepatic stellate cell activation
Tsuchida, T., & Friedman, S. L. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.38 · Cited by 2,909
Molecular and cellular mechanisms of liver fibrosis and its regression
Kisseleva, T., & Brenner, D. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00372-7 · Cited by 2,024 · cited 3×
“(1) MSCs can transdifferentiate into hepatocytes or merge with existing hepatocytes when introduced into injured liver tissue, making them a valuable resource for liver tissue regeneration and repair; (2) MSCs are capable of producing various cytokines, growth factors, and exosomes, which stimulate the regeneration of…”
BackgroundGinès, P., Krag, A., Abraldes, J. G., Solà, E., Fabrellas, N., & Kamath, P. S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01374-x · Cited by 1,663 · cited 12×
“The primary pathophysiology of liver fibrosis is increased collagen deposition of types I and III in the extracellular matrix (ECM) (1, 2).”
BackgroundInfluentialMesenchymal stem cell secretome: toward cell-free therapeutic strategies in regenerative medicine
Vizoso, F., Eiro, N., Cid, S., Schneider, J., & Perez-Fernandez, R. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091852 · Cited by 1,363 · cited 1×
“Frontiers in Immunology 03 IL-6, IL-8, and IL-9) to mediate their immunomodulatory effects (54).”
BackgroundWaterman, R. S., Tomchuck, S. L., Henkle, S. L., & Betancourt, A. M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010088 · Cited by 1,238
Zhang, S., Chuah, S. J., Lai, R. C., Hui, J. H. P., Lim, S. K., & Toh, W. S. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2017.11.028 · Cited by 919
Harrell, C. R., Jovicic, N., Djonov, V., Arsenijevic, N., & Volarevic, V. (2019) · Cells · doi:10.3390/cells8121605 · Cited by 795
Immune modulation by mesenchymal stem cells
Jiang, W., & Xu, J. (2020) · Cell Proliferation · doi:10.1111/cpr.12712 · Cited by 650 · cited 2×
“MSCs regulate both innate and adaptive immunity (47), and their immunomodulatory functions are predominantly exerted through cell-to-cell contact and paracrine activity with macrophages, monocytes, neutrophils, T cells, B cells and natural killer (NK) cells.”
BackgroundPeiseler, M., Schwabe, R., Hampe, J., Kubes, P., Heikenwälder, M., & Tacke, F. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.06.012 · Cited by 564 · cited 1×
“In addition, myofibroblasts are known to produce tissue inhibitors of matrix metalloproteinases (TIMPs) to prevent matrix metalloproteinases (MMPs) from degrading the ECM and maintaining ECM integrity (Figure 1) (31, 32).”
BackgroundImmunobiology and pathogenesis of hepatitis B virus infection
Iannacone, M., & Guidotti, L. G. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00549-4 · Cited by 520 · cited 1×
“In addition, myofibroblasts are known to produce tissue inhibitors of matrix metalloproteinases (TIMPs) to prevent matrix metalloproteinases (MMPs) from degrading the ECM and maintaining ECM integrity (Figure 1) (31, 32).”
BackgroundFallowfield, J. A., Mizuno, M., Kendall, T. J., Constandinou, C. M., Benyon, R. C., Duffield, J. S., & Iredale, J. P. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.8.5288 · Cited by 479
Zhang, Z., Lin, H., Shi, M., Xu, R., Fu, J., Lv, J., Chen, L., Lv, S., Li, Y., Yu, S., et al. (2012) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2011.07024.x · Cited by 372
Hepatic stellate cell autophagy inhibits extracellular vesicle release to attenuate liver fibrosis
Gao, J., Wei, B., de Assuncao, T. M., Liu, Z., Hu, X., Ibrahim, S., Cooper, S. A., Cao, S., Shah, V. H., & Kostallari, E. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.04.044 · Cited by 288
Coll, M., Perea, L., Boon, R., Leite, S. B., Vallverdú, J., Mannaerts, I., Smout, A., El Taghdouini, A., Blaya, D., Rodrigo-Torres, D., et al. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.05.027 · Cited by 233
Prockop, D. J. (2013) · Stem Cells · doi:10.1002/stem.1400 · Cited by 230 · cited 3×
“By secreting prostaglandin E2, MSCs convert proinflammatory M1 into anti-inflammatory M2 macrophages (PGE2) (48).”
BackgroundMesenchymal stem cell therapy for liver fibrosis
Eom, Y. W., Shim, K. Y., & Baik, S. K. (2015) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2015.30.5.580 · Cited by 226 · cited 1×
“These studies indicate that MSCs stimulate liver regeneration via immune regulation and paracrine mechanisms (25, 56, 60).”
BackgroundHuang, B., Cheng, X., Wang, H., Huang, W., la Ga hu, Z., Wang, D., Zhang, K., Zhang, H., Xue, Z., Da, Y., et al. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-0792-1 · Cited by 183
Zhang, X.-W., Zhou, J.-C., Peng, D., Hua, F., Li, K., Yu, J.-J., Lv, X.-X., Cui, B., Liu, S.-S., Yu, J.-M., et al. (2020) · Autophagy · doi:10.1080/15548627.2019.1635383 · Cited by 166
Self-citationWatanabe, Y., Tsuchiya, A., Seino, S., Kawata, Y., Kojima, Y., Ikarashi, S., Starkey Lewis, P. J., Lu, W.-Y., Kikuta, J., Kawai, H., et al. (2019) · Stem Cells Translational Medicine · doi:10.1002/sctm.18-0105 · Cited by 155
Shi, M., Li, Y.-Y., Xu, R.-N., Meng, F.-P., Yu, S.-J., Fu, J.-L., Hu, J.-H., Li, J.-X., Wang, L.-F., Jin, L., et al. (2021) · Hepatology International · doi:10.1007/s12072-021-10199-2 · Cited by 151 · cited 1×
“Among these, UCMSC is a promising stem cell that is expected to be produced commercially (95).”
BackgroundMesenchymal stem cell-based cell-free strategies: safe and effective treatments for liver injury
Hu, C., Zhao, L., Zhang, L., Bao, Q., & Li, L. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-01895-1 · Cited by 130
Li, M., Jiang, Y., Hou, Q., Zhao, Y., Zhong, L., & Fu, X. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-02822-2 · Cited by 119
Mesenchymal stem cell therapy for liver fibrosis/cirrhosis
Cao, Y., Ji, C., & Lu, L. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.02.119 · Cited by 99
Luo, X.-Y., Meng, X.-J., Cao, D.-C., Wang, W., Zhou, K., Li, L., Guo, M., & Wang, P. (2019) · Stem Cell Research & Therapy · doi:10.1186/s13287-018-1122-8 · Cited by 99 · cited 1×
“(72) demonstrate for the first time that BM-MSC transplantation promotes activation of MMP13-expressing M2 macrophages and suppresses M1 macrophages, which further inhibit HSCs, which play a synergistic role in attenuating liver fibrosis.”
BackgroundLee, K.-C., Lin, H.-C., Huang, Y.-H., & Hung, S.-C. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.07.035 · Cited by 85 · cited 1×
“Inflammatory factors released by M1 macrophages or activated T cells stimulate MSCs to secrete cytokines to differentiate monocytes toward the M2 type of the anti-inflammatory phenotype (53).”
BackgroundStem cells for treatment of liver fibrosis/cirrhosis: clinical progress and therapeutic potential
Liu, P., Mao, Y., Xie, Y., Wei, J., & Yao, J. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-03041-5 · Cited by 82 · cited 3×
“ESCs and iPSCs achieve therapeutic effects mainly by differentiating into mature hepatocytes in vitro or in vivo (8).”
BackgroundSelf-citationMesenchymal stromal cells: promising treatment for liver cirrhosis
Yao, L., Hu, X., Dai, K., Yuan, M., Liu, P., Zhang, Q., & Jiang, Y. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-03001-z · Cited by 71 · cited 11×
“TGF-b is the primary cytokine involved in the activation of HSC transdifferentiation and the EMT signal.”
BackgroundInfluentialSelf-citationMechanisms Underlying Cell Therapy in Liver Fibrosis: An Overview
Pinheiro, D., Dias, I., Ribeiro Silva, K., Stumbo, A. C., Thole, A., Cortez, E., de Carvalho, L., Weiskirchen, R., & Carvalho, S. (2019) · Cells · doi:10.3390/cells8111339 · Cited by 46
Mesenchymal stem cell-based Smad7 gene therapy for experimental liver cirrhosis
Su, D.-N., Wu, S.-P., & Xu, S.-Z. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-01911-4 · Cited by 33 · cited 4×
“MSCs were able to significantly down-regulate the mRNA expression of TGF-b1 and TGFBR1 downstream molecule SMAD3 and increase the mRNA expression of SMAD7 (71).”
BackgroundInfluentialQiao, H., Zhou, Y., Qin, X., Cheng, J., He, Y., & Jiang, Y. (2018) · Stem Cells International · doi:10.1155/2018/1239143 · Cited by 28 · cited 1×
“(70) proved that hBM-MSCs significantly inhibited the proliferation of activated HSCs by inducing the apoptotic process of activated HSCs.”
Background
Cited by
Mesenchymal stem cell therapy as a game-changer in liver diseases: review of current clinical trials
Huang, W.-C., Li, Y.-C., Chen, P.-X., Ma, K. S.-K., & Wang, L.-T. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-04127-y · Cited by 29
Cell therapy for end-stage liver disease: Current state and clinical challenge
Zhang, L., Deng, Y., Bai, X., Wei, X., Ren, Y., Chen, S., & Deng, H. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003332 · Cited by 12
“…[126,127] Moreover, evidence suggests that the inhibitory effect of MSCs on NK cells is attributed to PGE2, IDO, TGF-β 1, and NO secreted by MSCs. [128] Interestingly, MSC-EVs have been proven to contain functional mitochondria that are transferred to intrahepatic neutrophils to reduce the…”
Didamoony, M. A., Soubh, A. A., & Ahmed, L. A. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-024-01784-7 · Cited by 9
“Recent advances in liver fibrosis treatment have opened up new avenues of hope, such as stem cell therapy, which has shown encouraging results in preclinical and clinical trials [67].”
Slautin, V., Konyshev, K., Gavrilov, I., Beresneva, O., Maklakova, I., & Grebnev, D. (2024) · Current Stem Cell Research & Therapy · doi:10.2174/011574888x279940231206100902 · Cited by 7
Xu, Y., Wang, X.-S., Zhou, X.-L., Lu, W.-M., Tang, X.-K., Jin, Y., & Ye, J.-S. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i32.3766 · Cited by 7
Metadata
- Authors
- Liu, P., Qian, Y., Liu, X., Zhu, X., Zhang, X., Lv, Y., & Xiang, J.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2023-01-04
- Volume
- 13
- Pages
- 1096402-1096402
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W4313585893
- Cited by
- 37
- References
- 30
- FWCI
- 5.13
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.